**SUPPLEMENTARY MATERIAL**

**Supplementary Table 1.** Characteristics of clinical trials included in the analysis (n=538).

| Variable | Open-label (n=366) No. (%) | Blinded (n=148) No. (%) | Unclear (n=24) No. (%) |
|---|---|---|---|
| PRO differences favoring the experimental arm | 150 (41.0) | 72 (48.7) | 5 (20.8) |
| International | 143 (39.1) | 74 (50.0) | 7 (29.2) |
| Industry funding, fully or in part | 188 (51.4) | 100 (67.6) | 7 (29.2) |
| Sample size n>200 | 247 (67.5) | 83 (56.1) | 17 (70.8) |
| Year of publication ≥ 2014[a] | 100 (27.3) | 52 (35.1) | 4 (16.7) |
| PRO primary endpoint | 73 (20.0) | 51 (34.5) | 7 (29.2) |
| Disease stage | | | |
| Metastatic/Advanced | 173 (47.3) | 55 (37.2) | 10 (41.7) |
| Non metastatic/Local | 115 (31.4) | 47 (31.8) | 9 (37.5) |
| Both | 61 (16.7) | 31 (20.9) | 2 (8.3) |
| Unclear | 17 (4.6) | 15 (10.1) | 3 (12.5) |
| CONSORT-PRO summary score[b], mean (SD), [range] | 3.01 (1.44) [0-6] | 2.96 (1.47) [0-6] | 3.13 (1.39) [1-6] |

[a] This cut-off date was based on the publication of the CONSORT-PRO extension (7). PRO= Patient Reported Outcomes; CONSORT= CONsolidated Standards Of Reporting Trials; SD, standard deviation.

[b] The CONSORT PRO-summary score ranges from 0 to 6. The original CONSORT-PRO extension consists of 5 items, however, for the purpose of our study the item P6a was split in two, to maximize information on quality of PRO reporting.

**Supplementary Table 2.** Multivariable logistic regression model for the occurrence of PRO differences favoring the experimental treatment arm (sensitivity analysis considering trials with missing information on treatment concealment as "open-label", n=538)[a]

| Variable | OR (95% CI) | *P*[b] |
|---|---|---|
| Blinded (yes vs no) | 1.24 (0.83-1.86) | 0.30 |
| International (yes vs no) | 0.92 (0.60-1.40) | 0.68 |
| Industry funding, fully or in part (yes vs no) | 1.39 (0.93-2.08) | 0.11 |
| Sample size n>200 (yes vs no) | 0.63 (0.41-0.97) | 0.04 |
| Year of publication ≥ 2014 [c] | 0.95 (0.64-1.42) | 0.80 |
| PRO primary endpoint (yes vs no) | 1.65 (1.06-2.58) | 0.03 |
| Disease stage | | |
| Metastatic/Advanced vs Non metastatic/Local | 0.94 (0.61-1.44) | 0.77 |
| Both/unclear vs Non metastatic/Local | 0.93 (0.58-1.51) | 0.77 |
| CONSORT-PRO summary score [d] | 1.13 (1.00-1.29) | 0.06 |

[a] This table represents the association of key randomized controlled trial characteristics with the chance of finding statistically significant differences favoring the experimental arm. CI = confidence interval; OR = odds ratio; PRO= Patient Reported Outcomes; CONSORT= CONsolidated Standards Of Reporting Trials.
[b] 2-sided Wald chi-square test.
[c]This cut-off date was based on the publication of the CONSORT-PRO extension (7)
[d] The CONSORT PRO-summary score ranging from 0 to 6 was included in the model as a continuous variable. The original CONSORT-PRO extension consists of 5 items, however, for the purpose of our study the item P6a was split in two, to maximize information on quality of PRO reporting.

**Supplementary Figure 1.** Selection process of studies and summary of analyses performed